NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma…
Precision Medicine, Immunotherapy, and Artificial Intelligence (AI) as Key Topics VALENCIA, Spain, May 31, 2024 (GLOBE NEWSWIRE) -- The EAACI…
Local startup Oncobiotix to receive $100,000 to advance cancer and microbiome researchCALGARY, Alberta, May 31, 2024 (GLOBE NEWSWIRE) -- The…
Châtillon, France, May 31, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN:…
MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks…
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple…
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated…
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated…
Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology Paris,…